Evidence-Based Reviews

Injectable extended-release naltrexone for opioid dependence: 3 studies

Author and Disclosure Information

 

References

3. Sullivan M, Bisaga A, Pavlicova M, et al. Long-acting injectable naltrexone induction: a randomized trial of outpatient opioid detoxification with naltrexone versus buprenorphine. Am J Psychiatry. 2017;174:459-467.

Study design

  • N = 150 adults with OUD, randomized to outpatient opioid detoxification
  • Patients were randomized to BUP- or NTX-facilitated detoxification, followed by XR-NTX
  • BUP detoxification group underwent a 7-day BUP taper followed by a opioid-free week
  • NTX group received a 1-day BUP dose followed by 6 days of ascending doses of oral NTX, along with clonidine and other adjunctive medications.

Outcomes

  • NTX-assisted detoxification was significantly more successful for XR-NTX induction (56.1% vs 32.7%).

Conclusion

  • Compared with the BUP-assisted detoxification group, NTX-assisted detoxification appears to make it significantly more likely for patients to be successfully inducted to XR-NTX.

The evidence discussed here holds promise in addressing some of the major issues surrounding MAT. For suitable candidates, XR-NTX seems to be as efficacious an option as agonist (BUP) MAT, and its induction limitations could be overcome by using NTX-facilitated detoxification protocols.

Pages

Recommended Reading

USPSTF issues draft research plan on opioid use disorder prevention
MDedge Psychiatry
Vaping soars among American teens in 2018 survey
MDedge Psychiatry
Chronic opioid use during pregnancy linked with reduced head circumference in NAS newborns
MDedge Psychiatry
Insulin loses its starting spot
MDedge Psychiatry
Surgeon general takes on teen vaping; medical groups show support
MDedge Psychiatry
Opioids don’t top NSAIDs for chronic pain
MDedge Psychiatry
Extended-release naltrexone competes with buprenorphine-naloxone combo
MDedge Psychiatry
ICYMI: EP 01 Lorenzo Norris
MDedge Psychiatry
Best of Psychopharmacology: Stimulants, ketamine, benzodiazapines
MDedge Psychiatry
With hemp now legal, FDA reaffirms rules for cannabis compounds
MDedge Psychiatry